ArticleBMC cardiovascular disorders2020
Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisis.
Article in BMC cardiovascular disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Assessing Sarcocornia as a Salt Substitute: Effects on Lipid Profile and Gelatinase Activity.Nutrients · 2024Trial
- Effect of High Intensity Interval Training on Matrix Metalloproteinases in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy.Scientific reports · 2020Trial
- Hyperuricemia and Hypoxic Pulmonary Hypertension: Pathogenic Links, Clinical Evidence, and Emerging Therapeutic Insights.Cardiovascular drugs and therapy · 2026Review
- The JNJ0966 Significantly Reduces the Elevated Serum MMP-9 and Blood Pressure Observed in SHRs With Periodontitis.International dental journal · 2026Article
- Effects of antihypertensive therapy on matrix metalloproteinase-9 levels in controlled hypertensive patients.BMC cardiovascular disorders · 2026Article
- Prognostic Value of Matrix Metalloproteinase 9 (MMP9) in Patients Following Off-Pump Coronary Artery Bypass Grafting.Life (Basel, Switzerland) · 2025Article
- Endothelial Function Biomarkers in Hypertension.Current medicinal chemistry · 2025Review
- Oxidative Stress Biomarkers in Hypertension.Current medicinal chemistry · 2025Review
- Senescence Biomarkers and Trajectories of Frailty and Physical Function After Kidney Transplantation.Clinical transplantation · 2024Article
- Plasma Biomarkers for Hypertension-Mediated Organ Damage Detection: A Narrative Review.Biomedicines · 2024Review
- Decreased retinal and choroidal endothelial surface molecules in spontaneously hypertensive rats.Experimental eye research · 2023Article
- The extracellular matrix mechanics in the vasculature.Nature cardiovascular research · 2023Review
- Inflammatory cytokines are associated to lower glomerular filtration rate in patients with hypertensive crisis.Frontiers in cardiovascular medicine · 2022Article
- MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- A Multi-Objective Approach for Drug Repurposing in Preeclampsia.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMatrix metalloproteinase-9 (MMP-9) participates in the degradation of components of the extracellular matrix and it is involved in vascular remodeling and vasomotor changes. The aim of this study was to investigate the plasma levels of MMP-9 in acute vascular alterations due to hypertensive crisis.
methodsThis cross-sectional study was performed in 40 normotensive (NT) and 58 controlled hypertensive subjects (CHyp) followed up in outpatient clinic. Moreover, 57 patients with hypertensive emergency (HypEmerg) and 43 in hypertensive urgency (HypUrg), seen in emergency department, were also included. Hypertensive crisis was divided into HypEmerg, which was characterized by levels of systolic blood pressure (BP) ≥ 180 mmHg and/or diastolic BP ≥ 120 mmHg complicated with target-organ damage (TOD), and HypUrg, defined by BP elevation without TOD. Univariate and multivariate regression analysis was performed to identify the influence of independent variables on MMP-9 levels. A p-value < 0.05 was considered statistically significant.
resultsThe mean age was 43.5 years in the NT group (11 men); 57.7 years in the CHyp group (29 men); 59.4 years in the HypUrg group (21 men) and 62.4 years in the HypEmerg group (31 men). The age was statistically different in the NT group compared to other 3 groups. The mean BP was 116.5 ± 13.9/72.4 ± 10.6 mmHg for NT, 123.2 ± 12.6/79 ± 9.2 for CHyp, 194.1 ± 24.3/121.4 ± 17.3 for HypUrg and 191.6 ± 34.3/121.7 ± 18.8 mmHg for HypEmerg, respectively (p-value< 0.0001 between groups). MMP-9 levels were statistically different between the HypEmerg (2.31 ± 0.2 ng/mL) and HypUrg groups (2.17 ± 0.3 ng/mL) compared to the NT (1.94 ± 0.3 ng/mL) (p-value < 0.01 and p-value < 0.05, respectively) and CHyp groups (1.92 ± 0.2 ng/mL) (p-value < 0.01). Uric acid was the only independent variable for predicting MMP-9 levels (p-value = 0.001).
conclusionMMP-9 concentrations are significantly higher in the hypertensive crisis groups (urgency and emergency) compared to the control groups. Therefore, MMP-9 may be a biomarker or mediator of pathophysiologic pathways in cases of acute elevations of blood pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.